Seeking Alpha6dAutomated tone · neutral
Dividend Roundup: Starbucks, Pfizer, Micron, AbbVie, and moreSeeking Alpha7dAutomated tone · bearish
Pfizer to close penicillin unit, cut around 330 jobs in ItalySeeking Alpha8dAutomated tone · bullish
Pfizer’s Tukysa regimen approved in U.S. for front-line breast cancerSeeking Alpha11dAutomated tone · neutral
Notable healthcare headlines for the week: Pfizer, Sanofi, and Novartis in focusSeeking Alpha12dAutomated tone · neutral
AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilotSeeking Alpha13dAutomated tone · neutral
Pfizer says phase 3 data buoys Litfulo as a vitiligo treatmentSeeking Alpha14dAutomated tone · neutral
Pfizer eczema therapy archives significant skin clearance in mid-stage trialSeeking Alpha17dAutomated tone · bearish
Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuitsSeeking Alpha22dAutomated tone · bullish
BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world studyInvesting.com23dAutomated tone · bullish
Pfizer at U.S. All Stars Conference: growth shifts beyond covidSeeking Alpha25dAutomated tone · neutral
Pfizer to share higher overseas drug revenue with U.S. under new HHS contract: reportInvesting.com26dAutomated tone · neutral
Pfizer to share overseas drug revenue with HHS under pricing dealYahoo Finance37dAutomated tone · neutral
Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right NowSeeking Alpha39dAutomated tone · neutral
Novartis India inks $132M asset purchase deal with Pfizer for Minipress brandsSeeking Alpha42dAutomated tone · neutral
Pfizer, Medicus ink licensing deal worth up to $1B for antibody drug conjugateSeeking Alpha48dAutomated tone · bullish
Pfizer-backed Priovant wins FDA approval for lead assetSeeking Alpha49dAutomated tone · bullish
Pfizer, BioNTech win approval for updated COVID-19 shotYahoo Finance50dAutomated tone · bearish
Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?Yahoo Finance53dAutomated tone · bullish
Pfizer’s Turnaround is Gaining Traction, but Can New Products Offset its Patent Cliff?Yahoo Finance53dAutomated tone · bullish
Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?Yahoo Finance56dAutomated tone · neutral
Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets AheadSeeking Alpha61dAutomated tone · neutral
Notable trades: Netflix, Coca-Cola, Pfizer among notable namesSeeking Alpha62dAutomated tone · bullish
Valneva jumps as Lyme disease vaccine developed with Pfizer undergoes EU reviewInvesting.com63dAutomated tone · neutral
EMA validates Pfizer-Valneva Lyme disease vaccine applicationSeeking Alpha63dAutomated tone · neutral
Valneva outlines $145M-$160M 2026 revenue guidance while Pfizer targets Lyme decisions within 12 monthsSeeking Alpha64dAutomated tone · neutral
Pfizer CEO Bourla buys ~$1M worth of company sharesYahoo Finance65dAutomated tone · neutral
Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?Seeking Alpha66dAutomated tone · bullish
Pfizer extends rally to seventh straight sessionSeeking Alpha67dAutomated tone · neutral
Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focusSeeking Alpha68dAutomated tone · neutral
Insider trades: Microsoft, Meta, Pfizer among notable namesYahoo Finance70dAutomated tone · neutral
After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?Yahoo Finance72dAutomated tone · bearish
Pfizer repels Covid-19 sales tumble to raise 2026 guidanceInvesting.com72dAutomated tone · neutral
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cutsYahoo Finance72dAutomated tone · neutral
Pfizer Ducks Continued Covid Fallout As Hard-Fought Obesity Readout LoomsYahoo Finance72dAutomated tone · bullish
Pfizer’s Quarterly Results Beat Expectations on Cancer, Heart DrugsSeeking Alpha72dAutomated tone · bullish
Pfizer tops Q2 expectations, boosts revenue guidanceCNBC72dAutomated tone · bearish
Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugsYahoo Finance72dAutomated tone · bullish
Pfizer beats quarterly profit estimates on strong demand for blood thinner EliquisInvesting.com72dAutomated tone · bullish
Pfizer raises full-year revenue guidance amid jump in blood-thinner drug salesInvesting.com73dAutomated tone · neutral
Form 4 Pfizer For: 3 AugustInvesting.com73dAutomated tone · neutral
Pfizer earnings up next as dividend, pipeline face scrutiny